{
    "Trade/Device Name(s)": [
        "Dexcom G6 Continuous Glucose Monitoring System",
        "Dexcom G6 Glucose Program Continuous Glucose Monitoring System"
    ],
    "Submitter Information": "Dexcom, Inc.",
    "510(k) Number": "K200876",
    "Predicate Device Reference 510(k) Number(s)": [
        "K191450"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QBJ",
        "QDK"
    ],
    "Summary Letter Date": "November 3, 2020",
    "Summary Letter Received Date": "November 5, 2020",
    "Submission Date": "December 01, 2020",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [
        "Sensor/applicator"
    ],
    "Instrument(s)/Platform(s)": [
        "Dexcom G6 sensor/applicator",
        "BLE transmitter",
        "BLE enabled receiver",
        "Mobile app"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction",
        "Bluetooth Low Energy transmission"
    ],
    "Methodologies": [
        "Continuous glucose monitoring",
        "Factory calibration",
        "Optional manual calibration",
        "Joint Probability Algorithm (JPA)"
    ],
    "Submission Type(s)": [
        "System",
        "Instrument",
        "Software",
        "Reagent",
        "Accessory",
        "Component"
    ],
    "Document Summary": "FDA 510(k) summary for Dexcom G6 and Dexcom G6 Glucose Program continuous glucose monitoring systems for real-time management of diabetes via interstitial glucose measurement",
    "Indications for Use Summary": "Real-time continuous glucose monitoring system indicated for management of diabetes in persons age 2 years and older, replacing fingerstick testing and aiding in detection of hyper- and hypoglycemia; capable of autonomous communication with digitally connected devices for diabetes management",
    "fda_folder": "Clinical Chemistry"
}